Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Six ways Gavi will continue to immunise half the world's children amid vaccine backlash and a funding crisis.

BMJ (Clinical research ed.)·2026

Same author

Generative artificial intelligence in undergraduate paediatric nursing education: A scoping review of current applications and ethical considerations.

Nurse education today·2026

Same author

Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity.

Science advances·2026

Same author

The UK experience with hepatitis B immunoglobulin use following liver transplantation: wide variation in practice despite evidence supporting cost-effective HBIG-free prophylaxis.

Gut·2026

Same author

A modular platform for Sterically Masked Activated Cytokines (SMACks).

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Defense Recognition of a Stripe Rust Fungal Effector Is Uncoupled from Disease Outcomes in Wheat.

Molecular plant-microbe interactions : MPMI·2026

Same journal

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia.

Journal of viral hepatitis·2026

Same journal

HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D.

Journal of viral hepatitis·2026

Same journal

Assessing the Utility of Shortened Read Time of the Abbott Bioline HCV Test to Predict Viremia.

Journal of viral hepatitis·2026

Same journal

Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals With Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage.

Journal of viral hepatitis·2026

Same journal

Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs.

Journal of viral hepatitis·2026

Same journal

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States.

Journal of viral hepatitis·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 21, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Hepatitis E case series: A UK experience.

Anne Robins¹, Grace Dolman², Simon Williams¹

¹East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.

Journal of Viral Hepatitis

|June 2, 2022

Summary

This summary is machine-generated.

A 24-week course of ribavirin effectively treats chronic hepatitis E in immunocompromised patients, achieving a 100% success rate. Optimizing dosage and reducing immunosuppression may further improve outcomes for hepatitis E virus (HEV) infection.

Keywords:

EASL guidelines SVR hepatitis E ribavirin

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Sep 21, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

Hepatology
Virology
Immunology

Background:

Hepatitis E virus (HEV) infection is increasing, posing a risk for chronic infection in immunocompromised individuals.
Current management involves reducing immunosuppression and treating with ribavirin, but optimal dosing and duration remain unclear.

Purpose of the Study:

To evaluate the effectiveness of ribavirin treatment for chronic hepatitis E.
To determine the optimal duration and dosage of ribavirin for sustained virological response (SVR).

Main Methods:

Retrospective review of eight immunocompromised patients with chronic HEV infection treated between 2018 and 2021.
Patients received varying durations of ribavirin treatment (12 or 24 weeks) with median daily dose of 600 mg.
Treatment response assessed by sustained virological response at 12 (SVR12) and 24 weeks (SVR24).

Main Results:

A 12-week ribavirin course resulted in SVR in 40% (2/5) of patients.
A 24-week ribavirin course achieved 100% SVR (3/3) in the initial treatment group.
Patients who relapsed and received a second 24-week course also achieved SVR.

Conclusions:

A 24-week course of ribavirin demonstrates superior efficacy for achieving sustained virological response in chronic hepatitis E.
Maximizing ribavirin dosage (up to 800 mg daily) and carefully reducing immunosuppression are recommended for optimal treatment outcomes.